EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Padeletti, LuigiArnar, David O
Boncinelli, Lorenzo
Brachman, Johannes
Camm, John A
Daubert, Jean Claude
Kassam, Sarah
Deliens, Luc
Glikson, Michael
Hayes, David
Israel, Carsten
Lampert, Rachel
Lobban, Trudie
Raatikainen, Pekka
Siegal, Gil
Vardas, Panos
Kirchhof, Paulus
Becker, Rüdiger
Cosio, Francisco
Loh, Peter
Cobbe, Stuart
Grace, Andrew
Morgan, John
Issue Date
2010-10
Metadata
Show full item recordCitation
Europace. 2010, 12(10):1480-9Abstract
The purpose of this Consensus Statement is to focus on implantable cardioverter-defibrillator (ICD) deactivation in patients with irreversible or terminal illness. This statement summarizes the opinions of the Task Force members, convened by the European Heart Rhythm Association (EHRA) and the Heart Rhythm Society (HRS), based on ethical and legal principles, as well as their own clinical, scientific, and technical experience. It is directed to all healthcare professionals who treat patients with implanted ICDs, nearing end of life, in order to improve the patient dying process. This statement is not intended to recommend or promote device deactivation. Rather, the ultimate judgement regarding this procedure must be made by the patient (or in special conditions by his/her legal representative) after careful communication about the deactivation's consequences, respecting his/her autonomy and clarifying that he/she has a legal and ethical right to refuse it. Obviously, the physician asked to deactivate the ICD and the industry representative asked to assist can conscientiously object to and refuse to perform device deactivation.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldAdditional Links
http://dx.doi.org/10.1093/europace/euq275ae974a485f413a2113503eed53cd6c53
10.1093/europace/euq275
Scopus Count
Collections
Related articles
- Management of cardiac electrical implantable devices in patients nearing the end of life or requesting withdrawal of therapy: review of the Heart Rhythm Society 2010 consensus statement.
- Authors: Kramer DB, Ottenberg AL, Mueller PS
- Issue date: 2010 Dec
- Deactivation of implanted cardioverter-defibrillators at the end of life: results of the EHRA survey.
- Authors: Marinskis G, van Erven L, EHRA Scientific Initiatives Committee.
- Issue date: 2010 Aug
- The ethical and legal implications of deactivating an implantable cardioverter-defibrillator in a patient with terminal cancer.
- Authors: England R, England T, Coggon J
- Issue date: 2007 Sep
- ICD deactivation: review of literature and clinical recommendations.
- Authors: Thanavaro JL
- Issue date: 2013 Feb
- Perspectives on withdrawing pacemaker and implantable cardioverter-defibrillator therapies at end of life: results of a survey of medical and legal professionals and patients.
- Authors: Kapa S, Mueller PS, Hayes DL, Asirvatham SJ
- Issue date: 2010 Nov